Journal article
Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
MM Gresle
Journal of neurology, neurosurgery, and psychiatry | BMJ PUBLISHING GROUP | Published : 2014
Abstract
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. OBJECTIVES: We evaluated whether the measurement of serum phosphorylated neurofilament heavy chain (pNF-H) titre is likely to be a valid biomarker of axonal injury in multiple sclerosis (MS). METHODS: Serum pNF-H concentrations were measured by ELISA in cases with relapsing-remitting (RR)-MS (n=81), secondary progressive (SP) MS (n=13) and primary progressive (PP)-MS; n=6) MS; first demyelinating event (FDE; n=82); and unaffected controls (n=135). A subset of MS cases (n=45) were re-sampled on one or multiple oc..
View full abstractRelated Projects (2)
Grants
Funding Acknowledgements
This work was supported by Multiple Sclerosis Research Australia (Incubator grant to MG and HB; Postgraduate Research Scholarship awarded to LFD); CASS Foundation (Medical research grant to MG and HB); CharityWorks for MS (fellowship to MG); The National Health and Medical Research Council Australia (Project grant 628699 to HB, GS, TK; Career development Award 628856 to HB and 1024898 to RL; and AWP is an NHMRC Senior Research Fellow); NHMRC Centre for Research Excellence Grant 1001216 (fellowship support for MG); Beijing Nova Programme (xx2013045 to YL) and the National Natural Science Foundation of China (Nos. 81101038 to YL).